title: Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa.
abstract: Plasmodium falciparum response mechanisms to the major artemisinin-based combination therapies (ACTs) are largely unknown. Multidrug-resistance protein (MRP)-like adenosine triphosphate (ATP)-binding cassette transporters are known to be related to multidrug resistance in many organisms. Therefore, we hypothesized that sequence variation in pfmrp1 can contribute to decreased parasite sensitivity to ACT. Through sequencing of the pfmrp1 open reading frame for 103 geographically diverse P. falciparum infections, we identified 27 single-nucleotide polymorphisms (SNPs), of which 21 were nonsynonymous and 6 synonymous. Analyses of clinical efficacy trials with artesunate-amodiaquine and artemether-lumefantrine detected a specific selection of the globally prevalent I876V SNP in recurrent infections after artemether-lumefantrine treatment. Additional in silico studies suggested an influence of variation in amino acid 876 on the ATP hydrolysis cycle of pfMRP1 with potential impact on protein functionality. Our data suggest for the first time, to our knowledge, the involvement of pfMRP1 in P. falciparum in vivo response to ACT.
authors.affiliation: Malaria Research, Karolinska Institutet, Stockholm, Sweden. sabina.dahlstrom@gmail.com
authors.forename: Sabina
authors.initials: S
authors.lastname: Dahlström
authors.forename: Pedro E
authors.initials: PE
authors.lastname: Ferreira
authors.forename: M Isabel
authors.initials: MI
authors.lastname: Veiga
authors.forename: Nazli
authors.initials: N
authors.lastname: Sedighi
authors.forename: Lisa
authors.initials: L
authors.lastname: Wiklund
authors.forename: Andreas
authors.initials: A
authors.lastname: Mårtensson
authors.forename: Anna
authors.initials: A
authors.lastname: Färnert
authors.forename: Christin
authors.initials: C
authors.lastname: Sisowath
authors.forename: Lyda
authors.initials: L
authors.lastname: Osório
authors.forename: Hamid
authors.initials: H
authors.lastname: Darban
authors.forename: Björn
authors.initials: B
authors.lastname: Andersson
authors.forename: Akira
authors.initials: A
authors.lastname: Kaneko
authors.forename: Gwenaëlle
authors.initials: G
authors.lastname: Conseil
authors.forename: Anders
authors.initials: A
authors.lastname: Björkman
authors.forename: J Pedro
authors.initials: JP
authors.lastname: Gil
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000737:chemistry / Q000235:genetics*; D000349:Africa; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance / Q000235:genetics*; D004359:Drug Therapy, Combination; D006801:Humans; D016366:Open Reading Frames / Q000235:genetics; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012641:Selection, Genetic; D013548:Sweden; D014195:Travel
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000962:Antimalarials; D037621:Artemisinins